Capricor gains $4M for cell therapy for cardiology

A Maryland biotech upstart has garnered $4 million in angel backing to launch its commercial work in developing a new stem cell therapy for cardiology. Capricor will focus on commercializing the research work of Johns Hopkins University medical center's cardiology chief, Dr. Eduardo Marban. The company, which is led by his wife, Linda Marban, is seeking another $2 million in funds. Dr. Marban has been collecting heart cells that can be grown in the lab. By injecting them into damaged hearts, researchers have seen evidence that such stem cell therapies can repair tissue. A number of other stem cell groups are also engaged in a race to find the best stem cells for the process. And new research work is ongoing to provide new proof that the concept will work in trauma centers.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.